KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $470000.0.

  • TherapeuticsMD's Other Non-Current Assets rose 71034.48% to $470000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $470000.0, marking a year-over-year increase of 71034.48%. This contributed to the annual value of $130000.0 for FY2024, which is 6220.93% down from last year.
  • As of Q3 2025, TherapeuticsMD's Other Non-Current Assets stood at $470000.0, which was up 71034.48% from $428000.0 recorded in Q2 2025.
  • TherapeuticsMD's Other Non-Current Assets' 5-year high stood at $48.7 million during Q4 2021, with a 5-year trough of $58000.0 in Q2 2024.
  • In the last 5 years, TherapeuticsMD's Other Non-Current Assets had a median value of $253000.0 in 2021 and averaged $2.8 million.
  • Over the last 5 years, TherapeuticsMD's Other Non-Current Assets had its largest YoY gain of 1914980.24% in 2021, and its largest YoY loss of 9953.43% in 2021.
  • Quarter analysis of 5 years shows TherapeuticsMD's Other Non-Current Assets stood at $48.7 million in 2021, then plummeted by 99.48% to $253000.0 in 2022, then soared by 35.97% to $344000.0 in 2023, then tumbled by 62.21% to $130000.0 in 2024, then soared by 261.54% to $470000.0 in 2025.
  • Its last three reported values are $470000.0 in Q3 2025, $428000.0 for Q2 2025, and $211000.0 during Q1 2025.